key: cord-0267501-jdvc1df1
authors: Eichholz, Karsten; Tran, Tuan Hiep; Chéneau, Coraline; Tran, Thi Thu Phuong; Paris, Océane; Pugniere, Martine; Kremer, Eric J
title: Adenovirus-α-defensin complexes induce NLRP3-associated maturation of human phagocytes via TLR4 engagement
date: 2021-10-26
journal: bioRxiv
DOI: 10.1101/2021.10.26.465098
sha: 35438ecc145df5628fc379a448cd01bc6b454e1a
doc_id: 267501
cord_uid: jdvc1df1

Intramuscular delivery of human adenovirus (HAdV)-based vaccines leads to rapid recruitment of neutrophils, which then release antimicrobial peptides/proteins (AMPs). How these AMPs influence vaccine efficacy over the subsequent 24 hr is poorly understood. In this study, we asked if human neutrophil protein 1 (HNP-1), an α-defensin that influences the direct and indirect innate immune responses to a range of pathogens, impacts the innate response of human phagocytes to three HAdV species/types (HAdV-C5, -D26, -B35). We show that HNP-1 binds to the capsids, redirects HAdV-C5, -D26, -B35 to Toll-like receptor 4 (TLR4), which leads to internalization, an NLRP3-mediated inflammasome response, and IL-1β release. Surprisingly, IL-1β release was not associated with notable disruption of plasma membrane integrity. These data further our understanding of HAdV innate immunogenicity and may provide pathways to extend HAdV-based vaccines efficacy.

The immunogenicity of adenoviruses (AdVs) in the context of infection of immune suppressed individuals, 2 therapeutic gene transfer, and vaccines is a pressing issue. With the occurrence of SARS-CoV-2, AdV-based 3 (human and simian) vaccines are being administered on a global scale (1) . Human AdVs (HAdVs) are ~950 Å 4 diameter, nonenveloped proteinaceous particles containing a ~36,000 (± 9,000) double-stranded linear DNA 5 genome. There are currently 7 HAdV species (A-G) and >100 types based on serology and phylogeny. HAdVs 6 typically cause self-limiting respiratory, ocular, or gastro-intestinal tract infections in all populations regardless 7 of health standards, but infections can be lethal in immune-compromised individuals (2) . Due to their endemic 8 nature at military training facilities, live HAdV types 4 and 7 have been used as vaccines since the 1950s to 9 prevent severe respiratory illness in recruits (3) . AdV-based vaccines have also been approved in a prime/boost 10 regimen against Ebola virus in the EU and have been tested in more than 200 clinical trials (clinicaltrials.gov, 11 May 2021). 12 In the context of natural infections, gene transfer, or vaccination, neutrophils and professional antigen- 13 presenting cells (APCs) such as monocytes and dendritic cells (DCs) extravasate to the site of injection or 14 infection and detect danger-associated molecular patterns (DAMPs) or pathogen-associated molecular patterns (PAMPs). APCs differentiate between pathogens via their pattern recognition receptors on the cell surface, in 1 endosomal compartments, or in the cytosol. PRRs include Toll-like receptors (TLRs) (among which the most 2 thoroughly studied receptor is TLR4), the nucleotide-binding oligomerization domain (NOD)-leucine-rich 3 repeats (LRR)-containing receptors (NLR) (among which NLRP3 is the most thoroughly studied receptor to 4 induce the inflammasome), the retinoic acid-inducible gene 1-like receptors (RIG-1), and the C-type lectin 5 receptors. PRRs detect different PAMPs and DAMPs and hence, differentially affect the immune environment 6 that is made up of pro-inflammatory cytokines, chemokines and host defence proteins/peptides (HDPs). In 7 some inflammatory environments, monocytes mature into DCs and then migrate to lymphoid tissues to initiate 8 antigen-specific T-and B-cell responses. 9 Antimicrobial peptides (AMPs) are effector molecules of the innate immune system, and act via antibiotic-like 10 properties against a broad array of infectious agents (4, 5) , or by promoting the activation and maturation of 11 some APCs. Neutrophils are a rich source of AMPs: ~20% of their cytoplasmic content can be AMPs (6) . The 12 rapid release of HDPs acts as part of first-line responders to the disruption of tissue homeostasis (7) . 13 Lactoferrin, α -defensin, and cathelicidin (LL-37) are alarmins that also modulate innate and adaptive immune 14 responses by directly engaging pattern recognition receptors in antigen-presenting cells (4, 5) . Additionally, in 15 epithelial cells, α -defensins impair HAdV-C5, -A12 and -B35 infection by stabilizing an intrinsically 16 disordered region of the capsid vertex and thus prevents intracellular viral disassembly (8-10). 17 We recently reported how lactoferrin retargets HAdV-C5, -D26 and -B35 to TLR4 and initiates inflammasome 18 assembly and interleukin 1 beta (IL-1β) release without loss of membrane integrity (11) . The inflammasome, a 19 multiprotein platform consisting of a pattern recognition receptor that promotes aggregation of apoptosis-20 associated speck-like protein containing a CARD, recruits and auto-activates pro-caspase 1. Pro-caspase-1 21 auto-activation can be followed by removal of the N-terminus of gasdermin D (GSDMD), which initiates the 22 loss of plasma membrane integrity via pore formation (12) . Canonical and non-canonical NLRP3 23 inflammasome formation is preceded by transcriptional priming event needed to produce inflammasome 24 components and cytokines (13) . In primary human monocytes, LPS -TLR4 engagement can induce an 25 alternative inflammasome activation that is characterized by IL-1β secretion in the absence of a transcriptional 26 priming event, inflammasome aggregation, and pyroptotic cell death (14) . 27 Here, we expanded our understanding of how an α-defensin impacts innate immune sensing of HAdV-C5, -28 D26 and -B35, which were chosen based on their development as vaccines (15) (16) (17) (18) (19) (20) (21) (22) . Mechanistically, HNP-1 29 binds HAdV-C5, -D26, and -B35 with affinities in the nanomolar range, increases HAdV uptake via a re- 30 targeting to TLR4 complexes, which in turn induces NLRP3 inflammasome formation and release of IL-1β. 31 32 34 HNP-1 binds the HAdV-C5 capsid through electrostatic and hydrophobic interactions at the juxtaposition of 35 the penton base and fibre, and on hexon (8, 23) . These interactions can reduce HAdV-C5 and HAdV-B35 infection of A549 cells (transformed human lung epithelial cells) [7] . To better understand the interactions, we 1 quantified the affinity of human HNP-1 to HAdV-C5, -D26 and -B35by surface plasmon resonance (SPR) 2 analyses. We show that HNP-1 binds to HAdV-C5, -D26 and -B35 with KDs that varied from 37 to 76 nM 3 ( Figure 1A & B) with a two-state association-dissociation reaction ( Figure S1A ). 4 The receptors for HAdV-C5, -D26, and -B35 partially overlap in human DCs (24) : HAdV-C5 predominantly 5 uses DC-SIGN (CD209) (25, 26) ; HAdV-B35 predominantly uses CD46 (27) , and HAdV-D26 uses sialic acid- 6 bearing glycans (28) and CD46 (29) . We therefore tested the impact of HNP-1 on capsid uptake using ∆ E1 7 vectors containing reporter genes. Transgene expression was used as a surrogate for endocytosis, cytoplasmic 8 transport, delivery of the capsid to the nuclear pore, and detection of the transgene. We selected doses to have 9 ~30% of DCs expressing the vector-encoded transgene throughout this study. Consistent with earlier reports 10 (25), we found that HNP-1 increased (p Figure 1C ). HAdVs preincubated with 16 HNP-1, adding HNP-1 to the cell medium before HAdV, or adding HNP-1 to the medium after HAdV, all 17 increased uptake ( Figure S1B ). 18 IVIg, which contains a high level of HAdV-C5 neutralizing antibodies, does not prevent HAdV-C5 infection 19 of monocyte-derived DCs but, paradoxically, increases infection (30, 31) . To characterize the effects induced 20 by HNP-1, we compared the HAdVs complexed with IVIg or HNP-1. Generally, the impact of HNP-1 was 21 similar to IVIg ( Figure 1D ). We then combined HNP-1 and IVIg with each type to determine if a synergistic 22 effect occurred. However, IVIg did not increase further HNP-1-enhanced transgene expression by HAdV-C5, -23 D26 or -B35 ( Figure 1D ). 24 In addition to HNP-1-enhanced uptake by monocyte-derived DCs, we found that HNP-1increased HAdV-C5 25 and -D26 infection by monocytes ( Figure S1C ). By contrast, HNP-1 had no additive effect on HAdV-C5-or 26 D26-mediated transgene expression by monocyte-derived Langerhans cells (LCs), whereas it increased HAdV-27 B35-mediated transgene expression ( Figure S1D) . Together, these results demonstrated that HNP-1 binds to 28 three HAdV species/types and that its presence tended to increase HAdV infection by primary human APCs. maturation, we provide individual baselines to identify the impact of the complex. We used LPS throughou 5 the study as a TLR4 inducer to show the relative range of cytokines and chemokines produced. HAdV-D26 6 and -B35 induced a greater cytokine response than HAdV-C5 or mock-treated monocyte-derived DCs ( Figure   7 2A, 4 columns on the left). We found that HAdV-HNP-1 complexes increased the release primarily in IL 8 1α and IL-1β ( Figure 2A , the 2 nd group of 4 columns) compared to HNP-1-treated monocyte-derived DCs 9 When comparing the HAdV vs the HAdV-HNP-1 complexes, the addition of HNP-1 induced an increase in led nce C5, for r a oth. ack Ig.

To to DC out 26 ure

Cs.

in several cytokines (Figure 2A , the three pairs of columns on the right). The more marked effect of HNP-1 on 1 HAdV-C5 may be due to the lower effect of HAdV-C5 alone on monocyte-derived DCs (see raw data in 2 Figure S2A ). 3 We then quantified the release of mature IL-1β. The HNP-1 + HAdV complexes induced greater IL-1β release 4 than each HAdV alone, which increased from 4 to 24 h post-stimulation (p ≤ 0.017 and p ≤ 0.013, 5 respectively) ( Figure 2B) . Monocytes, which typically generate low levels of IL-1β, did not release more IL- 6 1β when challenged with HAdV-HNP-1 compared to HNP-1 alone ( Figure S2B ). To characterize the impact 7 of HNP-1 on monocyte-derived DCs, we compared HNP-1 to the effect induced by IVIg-complexed HAdVs. 8 We found that IVIg-complexed HAdV induced modestly more IL-1β release than HNP-1-complexed HAdVs 9 ( Figure 2C ). When IVIg and HNP-1 are combined with the HAdVs, a minor increase was also seen ( Figure   10 2C). Using phenotypic (CD86 surface level) and functional (changes in phagocytosis) assays, we found that 11 HNP-1increased DC maturation when using HAdV-C5 and -D26 ( Figure S2C-D) . Together, these data 12 demonstrated that HNP-1 increased the innate immune response to HAdV-C5 and -D26 and led to functional 13 and phenotypic maturation of monocyte-derived DCs. Notably, these data also mirror the increased efficacy of 14 HAdV infection induced by HNP-1.

HAdV-HNP-1 complexes induce monocyte-derived DC maturation through TLR4 engagement 16 As α-defensins are structurally similar to β -defensins, which can activate DCs in a TLR4-dependent manner 17 (32), we explored the possibility that HNP-1-enhanced HAdV transgene expression was due to TLR4 18 engagement. We used TAK-242, a cell-permeable cyclohexene-carboxylate, to disrupt TLR4 -TIRAP and 19 TRAM interactions, which influence NF-κB activation (33) (34) (35) . We found that TAK-242 reduced (p ≤ 0.019) 20 HNP-1-enhanced uptake of HAdV-C5, -D26 and -B35 ( Figure 3A ). The influence of TAK-242 on IL-1β 21 release ( Figure 3B ) reflected the infection assay: we found a reduction (p ≤ 0.045) post-incubation with 22 HAdV-C5 and -B35-HNP-1 challenge, but less prominent for HAdV-D26. Yet, in each case pre-incubation 23 with TAK-242 reduced extracellular IL-1β levels to background levels. Consistent with other reports, TAK- 24 242 reduced (p ≤ 0.05) TNF secretion induced by HNP-1-HAdV complexes and LPS ( Figure 3C ). Of note, 25 HNP-1 did not significantly enhance infection of monocytes or Langerhans cells ( Figure S3A & B) , 26 suggesting differences in TLR4 function(s) and/or stoichiometry between these APCs. 27 To assess the role of the extracellular TLR4 domain in HNP-1-enhanced infection, we used oxPAPC, which 28 interferes with TLR4 -MD2 interactions. oxPAPC reduced infection by HAdV-C5-or HAdV-D26-HNP-1 29 complexes (p< 0.043), but not HAdV-B35 ( Figure 3D) . We then used Pepinh-TRIF to inhibit cytoplasmic 30 TLR4 -TRIF interactions and found that Pepinh-TRIF had no effect on HAdV-C5 and -D26, but, surprisingly, 31 increased (p < 0.0007) HNP-1-HAdV-B35 infection ( Figure 3D) . Additionally, oxPAPC and Pepinh-TRIF 32 decreased (p ≤ 0.037) IL-1β release induced by HNP-1-HAdVs complexes ( Figure 3E ). Combined, these data 33 suggested that TLR4 signalling is involved in HNP-1-enhanced infection, and IL-1β and TNF production. MD-2 can form a complex with TLR4, with the former acting as a co-receptor for exogenous and endogenou 1 ligands (36) or with CD14, for ligand internalization (37) . We therefore assayed whether TLR4 engagement i 2 influenced by recombinant TLR4, MD-2, TLR4/MD-2 dimers, or a CD14-blocking antibody. Using thi 3 approach, only recombinant MD-2 notably modified HNP-1-enhanced infection by increasing (p ≤ 0.006 4 HAdV-C5 infection. Recombinant TLR4 trended (p > 0.05) toward an increase in HAdV-D26 infection 5 ( Figure 3F ). Together, these data are consistent with TLR4 complex engagement and that intracellular TLR4 6 signalling is involved in the sensing of HNP-1-complexed HAdV-C5, -D26 and -B35. To identify the HAdV-HNP-1-associated trigger(s) for inflammasome induction, monocyte-derived DCs were 1 pre-treated with KCl (to prevent K + efflux), N-acetyl-L-cysteine (NAC) (a ROS scavenger), and MDL (to 2 inhibit endosomal proteases-mediated activation of the NLRP3 inflammasome after endosome lysis) (12) . LPS 3 in the presence or absence of the NLRP3 inducer nigericin was used as a control. We found that only the Figure 4A ). Adding K + or NAC also modified HNP-1-enhanced infection by HAdV-C5 and -D26 1 ( Figure 4B ). Of note, following receptor-mediated endocytosis, HAdVs escape from endosomal compartments 2 via the endosomolytic activity of protein VI (38) . Therefore, these data are consistent with the idea that 3 endosomal rupture caused by HNP-1-enhanced uptake and cathepsin B release into the cytosol, which in turn 4 induces inflammasome induction and IL-1β release. 5 We then used small molecule inhibitors to dissect the crosstalk between TLR4-induced signalling and NLRP3 6 induction in the presence of HNP-1-HAdV complexes. DCs pre-incubated with R406 (blocking MyD88-Syk 7 interactions and interrupting the signalling between TLR4 engagement and NLRP3 inflammasome regulation), 8 or Bay11-7082 (inhibitor of NLRP3 (39)), IL-1β release was reduced (p ≤ 0.038) in response to HNP-1 9 complexes in all cases barring R406 along with HNP-1 and HAdV-D26 ( Figure 5A ). Bay11-7082 and R406 10 did not significant impact on HNP-1-enhanced infection (except for HAdV-B35) ( Figure 5B) . MCC950, an 11 NLRP3 inhibitor, also inhibited IL-1β release ( Figure 5C ). 12 We then inhibited selected caspases using VX765 (caspase-1 and -4), Z-IETD (capsase-8), WEHD (caspase-1, 13 -4, -5 and -8), and Z-YVAD-FMK (caspase-1, -4 and -5). We found that all the inhibitors reduced IL-1β 14 release to some extent (Figure 5D-G) . Importantly, the caspase inhibitors had no consistent effect on HNP-1- 15 enhanced infection (Figure S5A ). In the alternative inflammasome pathway, activation of the NLRP3 16 inflammasome depends on signalling through TLR4 and the kinase RIPK1, whereas the involvement of 17 kinases RIPK3 and MLKL downstream of RIPK1 is not required (14) . Consequently, we used GSK963 S5C for analyses broken down by HAdV type). 24 We concluded that HAdV-HNP-1 complexes induced NLRP3 inflammasome formation and IL-1β release via 25 the activation of the TLR4 pathway. Of note though, the pathway does not fully recapitulate all steps of the 26 alternative inflammasome pathway. Furthermore, the cellular factors involved in HNP-1-enhanced HAdV 27 infection are upstream of NLRP3, caspases and RIPK1, RIPK3 and MLKL kinases. 28 29 These data incited us to investigate the activation of the alternative inflammasome pathway (14) . To determine 30 whether HAdV-HNP-1 complexes induced the release cytoplasmic proteins, we quantified extracellular 31 activity of L-lactate dehydrogenase (LDH) at 4 h post-incubation. We found no notable (p > 0.05) increase in 32 any condition (Figure 6A) . To determine whether HAdV-HNP-1 complexes impacted membrane integrity, we 33 added 7-AAD and quantified its uptake by DCs. We found that the percentage of 7-AAD + cells induced by 34 HAdV-HNP-1 complexes was greater (p ≤ 0.044) than HNP-1-or HAdV-challenged cells (Figure 6B ). 35 Additionally, when HNP-1 was added to HAdV-IVIg complexes, a modest increase in the percentage of 7-1 allow small molecule entry were created, but LDH was not released into the medium, suggesting tha 2 pyroptosis was aborted. 

Here, we demonstrate how an α-defensin promotes innate immune sensing of HAdVs and maturation in 2 human DCs. We used biochemical, pharmaceutical, cellular, and molecular approaches to address HAdV 3 HNP-1 inflammasome formation/activation in primary human APCs. Our data demonstrate that HNP-1 bind 4 to the HAdV capsids, enhances the infection of human phagocytes, and engages TLR4 to induce pro 5 inflammatory cytokines via the NLRP3 inflammasome. 6 Based on their efficacy as vaccines and differences in receptor use, it was not surprising to observe similaritie 7 and notable differences between the HAdVs assayed in this study. Notably, HAdV-B35 also had the stronges 8 inflammatory response even though it was used at the lowest dose (1,000 pp/cell), which may be attributed to 9 the engagement of CD46 and the TLR4-NLRP3 axis described here. It is worth noting that CD46 engagemen 10 can induce the formation of the NLRP3 inflammasome in human CD4 + cells (40) . We speculate that the 11 individual attachment receptors for HAdV-C5 (CAR and DC-SIGN), HAdV-D26 and HAdV-B35 (CD46) and 12 their stoichiometry are involved in the differences reported here. Notably, CAR is not expressed on mos 13 human phagocytes, and crosstalk between TLR4 signalling with DC-SIGN or CD46, respectively, to induce 14 pro-inflammatory responses have been described and may account for the differences seen in our study (41 15 43). Of note, we did not directly address the differences in viral DNA entering the cells and acting as a PAMP 16 for TLR9 engagement (30) . (32, (44) (45) (46) this 4 synergistic effect likely plays a significant role in the downstream adaptive response. By exploring further 5 these early events, we address the mechanisms by which an α-defensin modifies innate and adaptive immune 6 responses to HAdVs. 7 Like lactoferrin, HNP-1-enhanced HAdV infection induced a pathway similar to the alternative NLRP3 8 inflammasome pathway (11) , which is characterized by the activation of TLR4-TRIF-RIPK1-FADD-CASP8 9 cascade and the absence of transcriptional priming step, K + efflux, and pyroptosome formation (14) . While the 10 key features are well aligned between the alternative pathway and our data, it is notable that the inhibition of 11 RIPK1 only partially abrogated IL-1β secretion induced by HNP-1, and that MLKL kinase may be involved in 12 the response to HAdV-D26 and -B35. These differences may be due to the cell types used (i.e. DC versus 13 monocytes) (14) , which express different levels of CD14 that affect TLR4 stoichiometry and signalling. More 14 importantly, LPS and HAdVs substantially differ in size, molecular composition, and functional factors that 15 affect intracellular processing and cytosolic PAMP detection. TLR4-mediated endocytosis of LPS involves 16 sequential interaction of CD14 and MD2 with LPS and depends on the homodimerization of TLR4. The shape 17 and size (~950 Å icosahedron) of the HAdV-HNP-1 complex allow HNP-1 to bind the capsid and induces 18 TLR4 dimerization or even multiple dimers directly. Quintessential TLR4 agonists do not have complex 19 intracellular processing. However, HAdVs traffic through endosomal compartments until the pH drops 20 sufficiently to allow capsid escape into the cytosol. When a HAdV capsid is covered with neutralizing 21 antibodies, lysosomal degradation of the capsids is more efficient, the viral genome is partially exposed, and 22 the DNA is then detected via TLR9 (30, 47) . Crosstalk between TLRs and synergistic effects on IL-1β 23 secretion has been previously reported for human DC (48) in vitro and in mice (49, 50) . Furthermore, 24 hierarchical dependency of cell surface receptors (TLR4) and intracellular PRRs in phagocytes can affect the 25 intracellular processing of the "ligand" (51) . Notably, also TLR4 engagement channels its ligands, in a TRIF- 26 dependent manner, into specialized intracellular compartments (52) and intracellular trafficking of a PAMP 27 through endosomal and lysosomal compartments and the cytosol can lead to differential signalling and the 28 production of type I IFN, TNF and IL-1β (53, 54) . In addition, HNP-1 increases the sensitivity of human 29 plasmacytoid DCs against TLR9 ligands and thus, promotes the induction of NF-κB and IRF1 response genes 30 (55, 56) . The range of our assays indicates that TLR4 signalling though MyD88 is required for HNP-1 31 enhanced HAdV infection while signalling through MyD88 and TRIF is required for the induction of the 32 NLRP3 inflammasome. We did not investigate how HAdV processing occurs downstream of TLR4-mediated 33 uptake, however, it is possible that the HNP-1-dependent increase of transgene expression coincides with 34 increased amounts of intracellular viral DNA and disrupted intracellular vesicles. It is possible that the higher 35 levels of viral DNA stimulate TLR9 or other PRRs and account for the differences seen between the 36 alternative inflammasome pathway and our data. Of note, our data also indicate that cathepsin B release from endosomal compartments concomitant with HAdV endosomal escape induces NLRP3 induction and IL-1β 1 secretion, which may further add to the differences seen by us and Gaidt et al. (14) . 2 Here, HAdV-HNP-1 induced signals are received immediately prior to NLRP3 engagement. We hypothesize 3 that the coordination of priming and de-ubiquitination of NLRP3 (57) , as well as TNF survival signals (58), 4 favour an adaptive immune response. Inflammasome activation is crucial for inducing cellular and humoral 5 immune responses. Recently, moderate NLRP3 activation in human conventional type 2 DCs induced a 6 hyperactivated phenotype characterized by secretion of IL-1β and IL-12 family cytokines in the absence of 7 pyroptosis and followed by strong induction of Th1 and Th17 responses (59) . Of note, HNP-1 also enhanced 8 HAdV-induced IL12-p40 secretion in our assays ( Figure. 2A) . We speculate that the involvement of the 9 HAdV-HNP-1-TLR4-NLRP3 axis may help drive the T-cell responses towards a Th1 phenotype. Recent 10 clinical trials indicate that Ad26.COV2.S, a HAdV-D26-based vaccine, induces potent Th1 responses against 11 the SARS-CoV-2 spike (60, 61) . It is conceivable that HNP-1 acts as a natural adjuvant and increases the 12 innate response and ultimately the breadth of the adaptive response to intracellular pathogens. In addition, 13 controlling this inflammatory response may be due to the production of IL-1α, which promotes cell survival 14 (62) . 15 In conclusion, we examined the multi-layered interface of human innate and adaptive responses to HAdV 16 pathogenesis and HAdV-based vaccines. 17 

Cells and culture conditions 19 Blood samples were purchased from the regional blood bank (EFS, Montpellier, France). An internal review 20 board approved their use. MoDCs were generated from freshly isolated or frozen CD14 + monocytes (30) . DC 21 stimulation was performed 6 d post-isolation. Monocyte-derived LC were generated using 200 ng/ml GM-CSF 22 and 10 ng/ml TGF-β. 911 and 293 E4-pIX cells were grown in Dulbecco's modified Eagle medium (DMEM) 23 and minimum essential medium (MEMα) with Earle's salts, L-glutamine supplemented with 10% foetal 24 bovine serum (FBS). 25 26 HAdV-C5 contained a GFP expression cassette (63) . HAdV-D26 contained a GFP-luciferase fusion expression 27 cassette (17) . HAdV-B35 contained a YFP expression cassette (8) . Vectors were propagated in 911 or 293 E4- 28 pIX cells and purified by density gradients (63) . For infection assays we used HAdV-C5 (5,000 physical 4 (Beckman) were used at 20 µg/ml. Inhibitors were added on cells and recombinant proteins or antibody were 5 added on HAdV-HNP-1 complex 1 h before stimulation. 6 Surface plasmon resonance analyses 7 SPR analyses were performed on a BIAcore 3000 apparatus in HBS-EP buffer (10 mM HEPES, 150 mM 8 NaCl, 3 mM EDTA, and 0.005% (v/v) polysorbate 20, pH 7.4). HAdV-C5, -D26 and -B35 diluted in acetate 9 buffer at pH 4 were immobilized on three flow cells of a CM5 sensor chip by amine coupling. Immobilization 10 levels were between 3,500 and 4,000 RU. A Blank flow cell was used as a control. HNP-1 was injected at 100 11 nM on the 4 flow cells simultaneously. T determine the KD, 6.25 -200 nM of HNP-1 was injected at 30 12 µl/min during 180s association and 600s dissociation with running buffer. Regeneration was performed with 13 Gly-HCl pH 1.7 pulses. The kinetic constants were assessed from the sensorgrams after double-blank 14 subtraction with BIAevaluation software 3.2 (GE Healthcare) (GE Healthcare) using a 2-state fitting model. 15 All experiments were repeated at least twice for each vector on a freshly coated flow cells. 16 Flow cytometry 17 GFP or YFP expression from the HAdV-C5, -B35, -D26 vectors was assayed by flow cytometry. CD86 18 surface expression level was assessed with an anti-CD86 antibody (clone 2331, APC, BD Biosciences). For 19 dextran uptake assays, we used 1 mg/ml for 30 min at 37°C, or 4°C for negative control) (dextran TRITC, 20 Sigma). Cell membrane integrity was assessed by collecting cells by centrifugation 800 x g, the cell pellets 21 were re-suspended in PBS, 2% FBS, 1 mM EDTA, 7-aminoactinomycin D (7-AAD) (Becton-Dickinson 22 Pharmigen) and analyzed on a FACS Canto II (Becton-Dickinson Pharmigen) or NovoCyte (ACEA 23 Biosciences) flow cytometer. 24 Cytokine secretion & LDH release 25 Supernatants were collected 4 or 24 h post-challenge and the levels of TNF and mature IL-1β were quantified 26 by ELISA using OptEIA human TNF ELISA Set (BD Biosciences) and human IL-1β/IL-1F2 DuoSet ELISA 27 (R&D systems). Twenty-two cytokines were detected using Bio-plex human chemokine, cytokine kit (Bio- 28 Rad). LDH release was quantified using an LDH Cytotoxicity Assay Kit (Thermo scientific) and as previously 29 described (11) . 30 Quantification of NLRP3, CASP1 and IL1B mRNAs 31 mRNAs levels were analyzed using qRT-PCR as previously described (11) . 32 The authors declare that there are no competing interests. 1 Data Availability 2 All data generated or analyzed during this study are included in this published article (and its supplementary 3 information files). 4 

A) Raw data of DCs ± HAdVs ± HNP-1, plus controls. Data indicated total protein level (ng). B) Freshly isolate human CD14 + monocytes were incubated with HAdV-C5-, -D26, or -B35 ± HNP-1. The supernatants (24 h post incubation) were used to quantify IL-1β release (n=6, statistical analyses by Student's t-test). There was no significant difference between HNP-1 vs. HNP-1+HAdVs. C) DCs were incubated with HAdV-HNP-1 complexe for 24 h. Phenotypic maturation was assessed by CD86 surface levels expression and functionally. D) DCs were incubated with HAdV-HNP-1 complexes and phagocytosis was quantified by fluorescent dextran uptake. Cells were incubated at 4°C or 37°C for 30 min with 1 mg/ml TRITC-labelled dextran, washed with PBS, fixed with 4% PFA and analyzed by flow cytometry (lower fluorescence = lower phagocytosis = greater maturation) (n =3, statistica analyses by two-tailed paired t-test). 63, dV 

Pros and Cons of Adenovirus-Based SARS-CoV-2 Vaccines

Adenovirus infections in immunocompetent and immunocompromised patients

Emergence and re-emergence of respiratory adenoviruses in the United States

AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense

The expanding scope of antimicrobial peptide structures and their modes of action

Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes

The next generation of antimicrobial peptides (AMPs) as molecular therapeutic tools for the treatment of diseases with social and economic impacts

Mechanism of adenovirus neutralization by human alpha-defensins

An intrinsically disordered region of the adenovirus capsid is implicated in neutralization by human alpha defensin 5

Direct evidence from single-cell analysis that human alpha-defensins block adenovirus uncoating to neutralize infection

Lactoferrin Retargets Human Adenoviruses to TLR4 to Induce an Abortive NLRP3-Associated Pyroptotic Response in Human Phagocytes

Mechanism and Regulation of NLRP3 Inflammasome Activation

Alternative inflammasome activation enables IL-1β release from living cells

Human Monocytes Engage an Alternative Inflammasome Pathway

Viral vectors as vaccine carriers

International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials

Low seroprevalent species D adenovirus vectors as influenza vaccines

Evaluation of Adenovirus Vectors Containing Serotype 35 Fibers for Vaccination

Development of group B adenoviruses as gene transfer vectors

High-level protein production in erythroid cells derived from in vivo transduced hematopoietic stem cells

Adenovirus vectors in hematopoietic stem cell genome editing

In vivo hematopoietic stem cell gene therapy ameliorates murine thalassemia intermedia

Delineation of Interfaces on Human Alpha-Defensins Critical for Human Adenovirus and Human Papillomavirus Inhibition

Adenovirus receptors: implications for tropism, treatment and targeting

CD209/DC-SIGN mediates efficient infection of monocyte-derived dendritic cells by clinical adenovirus 2C isolates in the presence of bovine lactoferrin

Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5

CD46 is a cellular receptor for group B adenoviruses

Human adenovirus type 26 uses sialic acidbearing glycans as a primary cell entry receptor

Human species D adenovirus hexon capsid protein mediates cell entry through a direct interaction with CD46

Immune-complexed adenovirus induce AIM2-mediated pyroptosis in human dendritic cells

Humoral immune response to adenovirus induce tolerogenic bystander dendritic cells that promote generation of regulatory T cells

Toll-Like Receptor 4-Dependent Activation of Dendritic Cells by -Defensin 2

TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway

LPS-TLR4 Signaling to IRF-3/7 and NF-κB Involves the Toll Adapters TRAM and TRIF

TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-β

MD-2, a Molecule that Confers Lipopolysaccharide Responsiveness on Toll-like Receptor 4

CD14 controls the LPS-induced endocytosis of Toll-like receptor 4

Adenovirus protein VI mediates membrane disruption following capsid disassembly

Anti-inflammatory compounds parthenolide and bay 11-7082 are direct inhibitors of the inflammasome

T helper 1 immunity requires complement-driven NLRP3

Induction of Proinflammatory Multiple Sclerosis-Associated Retrovirus Envelope Protein by Human Herpesvirus-6A and CD46 Receptor Engagement

DC-SIGN and Toll-like receptor 4 mediate oxidized low-density lipoprotein-induced inflammatory responses in macrophages

Lipopolysaccharide-induced DC-SIGN/TLR4 crosstalk activates NLRP3 inflammasomes via MyD88-independent signaling in gastric epithelial cells

Human defensins activate monocyte-derived dendritic cells, promote the production of proinflammatory cytokines, and up-regulate the surface expression of CD91

Monocyte-chemotactic activity of defensins from human neutrophils

Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils

Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells

Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells

Central role of toll-like receptor 4 signaling and host defense in experimental pneumonia caused by gram-negative bacteria

TLR9 Is Required for Protective Innate Immunity in Gram-Negative Bacterial Pneumonia: Role of Dendritic Cells

Noncanonical Autophagy Is Required for Type I Interferon Secretion in Response to DNA-Immune Complexes

Toll-like Receptor 4 Is a Sensor for Autophagy Associated with Innate Immunity

BAD-LAMP controls TLR9 trafficking and signalling in human plasmacytoid dendritic cells

AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC

Alarmin human α defensin HNP1 activates plasmacytoid dendritic cells by triggering NF-κB and IRF1 signaling pathways

Alarmin human α defensin HNP1 activates plasmacytoid dendritic cells by triggering NF-κB and IRF1 signaling pathways

Deubiquitination of NLRP3 by BRCC3 Critically Regulates Inflammasome Activity

Spontaneous apoptosis of dendritic cells is efficiently inhibited by TRAP (CD40 ligand) and TNF α , but strongly enhanced by interleukin 10

Select hyperactivating NLRP3 ligands enhance the T H 1-and T H 17-inducing potential of human type 2 conventional dendritic cells

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

Inflammasome-Independent Regulation of IL-1-Family Cytokines

Canine adenovirus vectors: an alternative for adenovirusmediated gene transfer

Elevated concentrations of human neutrophil peptides in plasma, blood, and body fluids from patients with infections

Plasma defensin concentrations are elevated in patients with septicemia or bacterial meningitis

Figure S1) Analyses of HNP-1 binding to HAdV-C5, -D26 and -B35 by SPR

A) HAdV-C5, -D26, and -B35 were covalently coupled to a CM5 sensor chip and escalating doses of HNP-1

Depicted are overlaid sensorgrams (RU = resonance units). B) Representative flow cytometry profiles of cells incubated with HAdVs ± HNP-1. DCs were mock-treated (grey), incubated with HAdV C5, -D26 and -B35 alone (red), with HNP-1 complexed with HAdV (blue), with HAdV for 30 min and then HNP-(green) or with HNP-1 for 30 min and then HAdV (purple). Fluorescence was analyzed 24 h post-incubation. C monocytes and D) LCs were incubated with HAdVs ± HNP-1 and GFP/YFP expression was analyzed 24 h post incubation

 33 We thank Eric Weaver and Andre Lieber for HAdV-D26 and -B35 vectors. We acknowledge the MRI (ANR- 34